PD1 Inhibitors Combined With Clostridium Butyricum for Urothelial Carcinoma

This study intends to explore whether the combination of Clostridium butyricum can improve the current situation of poor anti-PD1 treatment effect in patients with bladder cancer.

Trial Details

NCT ID
NCT06696742
Phase
PHASE2
Sponsor
The First Affiliated Hospital with Nanjing Medical University
Status
RECRUITING
Cancer Type
Urothelial Carcinoma Bladder Cancer
Interventions
  • Clostridium Butyricum Tablets
  • Cisplatin
Locations (sample)
  • Nanjing, Jiangsu, China|32.06167,118.77778

Key Eligibility Criteria

  • For Neoadjuvant therapy:
  • T2-T4aN0M0 bladder patients
  • For Adjuvant therapy:
  • Postoperative pathological stage T3-T4 and/or lymph node metastasis were positive.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Urothelial Carcinoma Bladder Cancer Trials on Trialify →